Cato Institute Calls for the Rescheduling of Cannabis

According to a February report by the Cato Institute, US
cannabis policy is “contradictory and confusing.”  The think tank recommended as a result, that
policy makers change what the organization called “bizarre” federal
policies. 

This marks yet another prestigious organization which has
joined the now growing reform movement.  
Cato comes at the issue from the right-wing, as many reform advocates
do.  Rand Paul is perhaps the most
visible national voice from this perspective, but he is not the only one.

This impact of ongoing national opinion has continued to
change everything from establishing regulations to the still thorny banking
issues the community currently faces.

The Cato Institute report suggests the rescheduling
compromise as many have suggested before, and recommends that cannabis should
become a Schedule II drug.  Schedule II
drugs include Adderall, Ritalin, and pain management opioids including
oxycodone. 

According to Cato, rescheduling would be a “substantial
improvement over current policy: It reduces the black market for [cannabis], scales
back enforcement expenditure and rationalizes current law, all while freeing
many [cannabis] users from ill-advised legal threats and penalties.”